GEHC · GE HealthCare Technologies Inc.
Price & Indicators
Up next
Metrics snapshot
Useful current figures from the complete screener profile.
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders SellIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Medical Devices — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
GEHC
this stock
GE HealthCare Technologies Inc.
|
$29.32B | -21.8% | +4.8% | 15.5 | 4.2% |
|
ABT
Abbott Laboratories
|
$178.73B | -18.1% | +5.7% | 28.7 | 1.3% |
|
MDT
Medtronic plc
|
$117.85B | -4.1% | +8.4% | 22.7 | 0.9% |
|
SYK
Stryker Corp
|
$105.53B | -21.7% | +11.2% | 28.5 | 2.0% |
|
BSX
Boston Scientific Corp
|
$64.27B | -54.5% | +12.5% | 18.0 | 3.3% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| GEHC | +0.3% | -13.4% | -7.4% | -10.0% | -21.8% |
| SPY | -0.3% | -0.1% | +20.1% | -0.7% | +11.7% |
| vs SPY | +0.7% | -13.3% | -27.5% | -9.3% | -33.5% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.